Compare IAE & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
| Metric | IAE | VANI |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | IAE | VANI |
|---|---|---|
| Price | $7.31 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 46.3K | ★ 167.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.31 | $0.91 |
| 52 Week High | $6.45 | $1.92 |
| Indicator | IAE | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 45.19 |
| Support Level | $7.20 | $1.25 |
| Resistance Level | $7.35 | $1.55 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 51.13 | 40.00 |
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.